Genetic Signatures

Genetic Signatures Current Assets

The Current Assets of Genetic Signatures (GSS.AX) as of Oct 28, 2026 is 32.43 M AUD. In the previous year, Current Assets was 52.21 M AUD — a change of -37.90% (lower).

Current Assets

32.43 MAUD

YoY

-37.90%

Last updated:

Current Assets of Genetic Signatures is 2026 32.43 M AUD. Current Assets of Genetic Signatures was 2025 52.21 M AUD. It decreases by -37.90% lower compared to the previous year.

The Genetic Signatures Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2019
10.67 M AUD
Jan 1, 2020
48.76 M AUD
Jan 1, 2021
47.63 M AUD
Jan 1, 2022
51.23 M AUD
Jan 1, 2023
43.24 M AUD
Jan 1, 2024
56.33 M AUD
Jan 1, 2025
52.21 M AUD
Jan 1, 2026
32.43 M AUD
The Genetic Signatures Current Assets history
YEARCurrent AssetsYoY
32.43 MAUD-37.90%
52.21 MAUD-7.31%
56.33 MAUD+30.27%
43.24 MAUD-15.60%
51.23 MAUD+7.57%
47.63 MAUD-2.32%
48.76 MAUD+356.76%
10.67 MAUD-34.63%
16.33 MAUD-12.17%
18.59 MAUD+173.82%
6.79 MAUD-17.63%
8.24 MAUD-50.98%
16.82 MAUD+2,147.71%
748,123.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genetic Signatures Stock analysis

What does Genetic Signatures do? Genetic Signatures Ltd. develops real-time PCR based products for infectious disease detection, focusing on the 3base platform technology. The company commercializes its MDx 3base platform, enabling high-volume hospitals and pathology labs to screen for infectious pathogens with high specificity and rapid results. Products under the EasyScreen brand include the EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, and EasyScreen Viral Meningitis Detection Kit, sold into diagnostic and research marketplaces. The firm targets hospitals and pathology laboratories as key buyers of its diagnostic solutions. Its products are designed for routine detection of infectious diseases, with the EasyScreen suite addressing specific pathogen categories like enteric, STI, and viral meningitis. The company focuses on research and commercialization of genetic signature identification for disease detection, leveraging its 3base platform for high-throughput screening. Genetic Signatures Ltd. generates revenue through the sale of its real-time PCR based products under the EasyScreen brand. The MDx 3base platform technology is central to its commercial strategy, providing a solution for rapid, specific pathogen screening in clinical settings. The company's product portfolio includes multiple kits targeting different infectious disease categories, all sold into the diagnostic and research markets. Genetic Signatures is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genetic Signatures stock

Current Assets of Genetic Signatures is 32.43 M AUD in 2026.

Current Assets of Genetic Signatures changed from 52.21 M AUD to 32.43 M AUD, representing a -37.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Genetic Signatures since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Genetic Signatures historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Genetic Signatures

All Key Metrics — Genetic Signatures